Drug

Hydroxyurea (Hydrea)

An oral capsule that lowers blood counts in chronic myeloid leukaemia and myeloproliferative diseases

Updated: 27 October 20261 min read3 references
Generic name
Hydroxyurea
Brand names
Hydrea
Drug class
Antimetabolite (ribonucleotide reductase inhibitor)
Route
Oral (capsule)
Show content for:

Key points

  • Hydroxyurea is a capsule that reduces the making of blood cells; your doctor adjusts the dose based on blood tests [1].
  • In chronic myeloid leukaemia, it brings a high white count down until targeted treatment starts [3].
  • In high-risk thrombocythaemia, it lowered the risk of blood clots [2].
  • Regular blood tests are needed; the dose is lowered with kidney failure [1].

What is this drug and how does it work?

For patients

Hydroxyurea slows DNA production in rapidly dividing cells and lowers blood cell and platelet counts [1].

For physiciansSpecialist notes
For physicians

Inhibits ribonucleotide reductase and stops DNA synthesis in S phase [1].

Which cancers is it used for?

For patients
What is this drug for?
  • Chronic myeloid leukaemia (rapidly lowering a high white count before targeted treatment, or with resistance) [1, 3]
  • Head and neck cancer with chemoradiotherapy [1]
  • High-risk polycythaemia vera and essential thrombocythaemia (common use) [2]
For physiciansApproved uses and evidence
For physicians
Approved uses and evidence
DiseaseUseKey evidence
Resistant CMLLabel [1]Now mostly for temporary cytoreduction before a TKI [3]
High-risk essential thrombocythaemiaPlatelet reductionFewer thromboses than no treatment [2]
Squamous cell head and neck cancerWith chemoradiotherapy [1]—

How it is taken and dosing

Show detailsHide

Swallow the capsule whole with water and do not open it; anyone handling the capsules (especially a pregnant woman) should wear gloves or wash their hands afterwards [1]. The dose is set by weight and blood tests.

For physiciansStandard dosing (FDA label), 1 regimen
For physicians

Standard dosing (FDA label)

Hydroxyurea

By diseaseCycle length: Daily

By disease

DrugDoseRouteSchedule
HydroxyureaIndividualised by disease, response and blood counts (actual or ideal weight, whichever is lower)OralDaily
Cycle length
Daily
Duration
By response

Creatinine clearance below 60 mL/min: reduce the dose by 50%. Blood counts before starting and regularly; stop with severe myelosuppression [1].

Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.

Side effects

For patients

The most common side effects: low blood counts, nausea, diarrhoea or constipation, mouth sores, and changes in the skin and nails [1].

For physiciansSpecialist notes
For physicians

Myelosuppression (leucopenia first), gastrointestinal symptoms, skin changes, macrocytosis [1].

Serious side effects

For patients

Serious side effects: very low blood counts, skin ulcers (especially on the lower legs) and, with long-term use, skin cancer [1].

For physiciansSpecialist notes
For physicians
  • Myelosuppression [1].
  • Secondary malignancies (leukaemia, skin cancer): sun protection and skin checks [1].
  • Cutaneous vasculitic toxicity and leg ulcers [1].
  • Live vaccines are contraindicated [1].

When should I call my doctor?

  • Fever or signs of infection
  • Bleeding or bruising
  • A skin sore that does not heal
  • A new change in a mole or the skin

Interactions, pregnancy and precautions

  • Vaccines: do not have live vaccines [1].
  • Skin: protect yourself from the sun [1].
  • Pregnancy: this drug may harm an unborn baby; use effective contraception during treatment and tell your doctor straight away if you become pregnant. Do not breastfeed during treatment; men should also use effective contraception during treatment and for some time afterwards [1].
For patients

Frequently asked questions

Is hydroxyurea chemotherapy?

Yes, it is a mild oral chemotherapy drug; in blood disorders it is usually taken for years at a low dose with regular blood tests [1].

References

3 references
Show all references, 1 with a study cardClose the reference list

Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.

  1. 1
    HYDREA (HYDROXYUREA) — Prescribing InformationH2-Pharma LLC · FDA label · 2026
    Source Back to text: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
  2. 2
    Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosisCortelazzo S, Finazzi G, Ruggeri M, et al · N Engl J Med · 1995;332:1132-6
    DOIPubMed Back to text: 1 2 3
  3. 3
    European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemiaHochhaus A, Baccarani M, Silver RT, et al · Leukemia · 2020;34:966-984
    Study cardDOIPubMed Back to text: 1 2 3

This page is based on reputable scientific sources and was last updated on 27 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.